Journals / Turkish Journal of Hematology / 2013 / Cilt: 30 - Sayı: 3

Akut lenfoblastik lösemi tedavisi sonrası yaşayan çocuklarda endokrinolojik ve kardiyolojik geç yan etkiler

Endocrinological and cardiological late effects among survivors of childhood acute lymphoblastic leukemia

Pages
290–299
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: We point out the necessity of follow-up of these patients for endocrinological and cardiological late effects, since at least one adverse event occurred in most of our cases.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Survival rates for childhood acute lymphoblastic leukemia (ALL) have significantly improved and late effects of therapy have been important in the follow-up of survivors.
📊
Key Findings & Data:Materials and Methods: Patients treated for ALL with BFM protocols after at least 5 years of diagnosis and not relapsed were included in the study.
💡
Conclusion & Impact:Conclusion: We point out the necessity of follow-up of these patients for endocrinological and cardiological late effects, since at least one adverse event occurred in most of our cases.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Survival rates for childhood acute lymphoblastic leukemia (ALL) have significantly improved and late effects of therapy have been important in the follow-up of survivors. The objective of this study is to identify the endocrinological and cardiological late effects of ALL patients treated in our pediatric hematology unit. Materials and Methods: Patients treated for ALL with BFM protocols after at least 5 years of diagnosis and not relapsed were included in the study. Endocrinological late effects (growth failure, obesity, insulin resistance, dyslipidemia, thyroid gland disorders, osteopenia/osteoporosis, and pubertal disorders) and cardiological late effects were evaluated. The study group was evaluated with anthropometric measurements, body mass index, and laboratory testing of fasting glucose, insulin, serum lipids, thyroid functions, and bone mineral densities. Echocardiography and pulsed wave Doppler imaging were performed for analysis of cardiac functions. Results: Of the 38 ALL survivors, at least 1 adverse event occurred in 23 (60%), with 8 of them (21%) having multiple problems. Six (16%) of the survivors were obese and 8 (21%) of them were overweight. Subjects who were overweight or obese at the time of diagnosis were more likely to be overweight or obese at last follow-up. Obesity was more frequently determined in patients who were younger than 6 years of age at the time of diagnosis. Insulin resistance was observed in 8 (21%) subjects. Insulin resistance was more frequently seen in subjects who had family history of type 2 diabetes mellitus. Hyperlipidemia was detected in 8 (21%) patients. Hypothyroidism or premature thelarche were detected in 2 children. Two survivors had osteopenia. Cardiovascular abnormalities occurred in one of the subjects with hypertension and cardiac diastolic dysfunction. Conclusion: We point out the necessity of follow-up of these patients for endocrinological and cardiological late effects, since at least one adverse event occurred in most of our cases.

Özet

Amaç: Akut lenfoblastik lösemili (ALL) çocuklarda sağkalım oranı belirgin düzelmiş ve izlemlerde geç yan etkiler açısından değerlendirilmeleri önemli hale gelmiştir. Bu çalışmanın amacı çocuk hematoloji kliniğimizde tedavisi tamamlanan akut lösemi olgularında uzun dönemde gelişebilecek endokrinolojik ve kardiyolojik geç etkilerin belirlenmesidir. Gereç ve Yöntemler: Lösemi tanısı aldığı tarihten itibaren en az beş yıl geçmiş, relaps gelişmemiş ve BFM protokolleri ile tedavi edilmiş hastalar endokrinolojik geç etkiler (boy kısalığı, obezite, insülin direnci, dislipidemi, tiroid hastalığı, osteopeni/ osteoporoz, puberte sorunları) ve kardiyolojik geç etkiler açısından değerlendirildi. Çalışma grubunda antropometrik ölçümler, vücut kitle indeksi, açlık kan şekeri, insülin, serum lipid ve tiroid fonksiyon testleri ve kemik mineral dansiteleri araştırıldı. Kardiyak fonksiyonların analizinde ekokardiyografi ve pulsed Doppler görüntüleme kullanıldı. Bulgular: 38 olgudan 23’ünde (%60) en az bir, 8 olguda (%21) ise birden fazla geç etki olduğu görüldü. Altı olgunun (%16) fazla kilolu, 8’inin (%21) obez olduğu belirlendi. Tanı anında fazla kilolu ya da obez olanlarda ve tedavi bitiminde fazla kilolu ya da obez olanlarda son değerlendirmede obezite daha yüksek orandaydı. Tanı anında altı yaşın altında olanlarda obezite daha fazlaydı. Sekiz olguda (%21) insülin direnci vardı. Obez ya da fazla kilolu olanlarda ve ailede tip 2 DM öyküsü bulunanlarda insülin direnci daha yüksek oranda bulundu. Sekiz olguda (%21) hiperlipidemi saptandı. Hipotiroidi veya prematür telarş birer olguda, osteopeni 2 olguda görüldü. Kardiyolojik geç etki olarak bir olguda hipertansiyon ve hafif diastolik disfonksiyon olduğu belirlendi. Sonuç: Olguların çoğunda en az bir geç yan etki gözlendiğinden, bu çocukların endokrinolojik ve kardiyolojik geç etkiler açısından takip edilmelerinin gerekli olduğu ortaya çıkmaktadır .

🔖

Cite This Article

KARAKAYA, P., YILMAZ, Ş., TÜFEKÇİ, Ö., KIR, M., BÖBER, E., İRKEN, G., ÖREN, H. (2013). Akut lenfoblastik lösemi tedavisi sonrası yaşayan çocuklarda endokrinolojik ve kardiyolojik geç yan etkiler. Turkish Journal of Hematology, Cilt: 30 - Sayı: 3, 290–299. https://ajindex.com/articles/413317

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Tonorezos ES, Oeffinger KC. Survivorship after childhood, adolescent, and young adult cancer. Cancer J 2008;14:388- 395
  2. Lag R, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Eisner MP, Horner MJ, Howlader N, Hayat M, Hankey BF Edwards BK (eds). SEER Cancer Statistics Review, 1975-2003. Bethesda, National Cancer Institute. Available at
  3. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL, Leisenring W, Robison LL; Childhood Cancer Survivor Study. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006;355:1572-1582
  4. Geenen MM, Cardous-Ubbink MC, Kremer LC, van den Bos C, van der Pal HJ, Heinen RC, Jaspers MW, Koning CC, Oldenburger F Langeveld NE, Hart AA, Bakker PJ, Caron HN, van Leeuwen FE. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA 2007;297:2705-2715
  5. Langeveld NE, Ubbink MC, Last BF Grootenhuis MA, Voûte PA, De Haan RJ. Educational achievement, employment and living situation in long-term young adult survivors of childhood cancer in the Netherlands. Psychooncology 2003;12:213-225
  6. Hudson MM, Mertens AC, Yasui Y, Hobbie W, Chen H, Gurney JG, Yeazel M, Recklitis CJ, Marina N, Robison LR, Oeffinger KC; Childhood Cancer Survivor Study Investigators. Health status of adult long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. JAMA 2003;290:1583-1592
  7. Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W, Niemeyer C, Henze G, Feldges A, Zintl F Kornhuber B, Ritter J, Welte K, Gadner H, Riehm H. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian- Swiss ALL-BFM Study Group. Blood 2000;95:3310-3322
  8. Centers for Disease Control and Prevention. Growth Charts. Atlanta, CDC, 2010. Available at http://www.cdc.gov/ growthcharts/
  9. Valerio G, Licenziati MR, Iannuzzi A, Franzese A, Siani P, Riccardi G, Rubba P. Insulin resistance and impaired glucose tolerance in obese children and adolescents from Southern Italy. Nutr Metab Cardiovasc Dis 2006;16:279-284
  10. American Academy of Pediatrics. National Cholesterol Education Program: Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992;89:525-584
  11. Lewiecki EM, Gordo